Submissions for variant NM_000540.3(RYR1):c.14173G>C (p.Val4725Leu)

dbSNP: rs1049117716

Total submissions: 6

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
ClinGen Congenital Myopathies Variant Curation Expert Panel, ClinGen	RCV004993957	SCV005619842	uncertain significance	RYR1-related myopathy	2024-08-27	reviewed by expert panel	curation	The c.14173G>C variant in RYR1 is a missense variant predicted to cause substitution of valine by leucine at amino acid 4725. The highest population minor allele frequency in gnomAD v4.1 is 0.00001667 (1/59980 alleles) in the Admixed American population, which is lower than the ClinGen Congenital Myopathies VCEP threshold (absent, 1 allele allowed) for PM2_Supporting, meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.661, which is neither above nor below the thresholds predicting a damaging or benign impact on RYR1 function. In summary, the variant meets the criteria to be classified as uncertain significance for RYR1-related myopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: PM2_Supporting (ClinGen Congenital Myopathies VCEP specifications version 2; 08/27/2024).
Labcorp Genetics (formerly Invitae), Labcorp	RCV000692536	SCV000820363	uncertain significance	RYR1-related disorder	2024-07-05	criteria provided, single submitter	clinical testing	This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 4725 of the RYR1 protein (p.Val4725Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of autosomal recessive RYR1-related conditions (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 571399). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics	RCV000764200	SCV000895203	uncertain significance	Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion	2018-10-31	criteria provided, single submitter	clinical testing
Illumina Laboratory Services, Illumina	RCV000692536	SCV002540238	uncertain significance	RYR1-related disorder	2022-01-05	criteria provided, single submitter	clinical testing	The RYR1 c.14173G>C (p.Val4725Leu) missense variant results in the substitution of valine at amino acid position 4725 with leucine. To our knowledge, this variant has not been reported in the peer-reviewed literature. This variant is not found in version 2.1.1 or version 3.1.2 of the Genome Aggregation Database. Based on the available evidence, the c.14173G>C (p.Val4725Leu) variant is classified as a variant of uncertain significance for RYR1-related disorders.
Revvity Omics, Revvity	RCV003133534	SCV003812451	uncertain significance	not provided	2021-10-05	criteria provided, single submitter	clinical testing
All of Us Research Program, National Institutes of Health	RCV003999585	SCV004832708	uncertain significance	Malignant hyperthermia, susceptibility to, 1	2024-05-14	criteria provided, single submitter	clinical testing	This missense variant replaces valine with leucine at codon 4725 of the RYR1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with RYR1-related disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.